Furthermore, recent investigations have underscored the frequent upregulation of COX2 in a range of human cancers, including melanoma, colorectal, breast, stomach, lung, and pancreatic tumors [28,29] Previous research has demonstrated the efficacy of COX2 inhibition in overcoming therapeutic resistance in BRAF V600E colorectal cancer [30] and its pivotal role in addressing drug resistance in melanoma [22,31,32]. This evidence concerns the gene BRAF and pancreatic neoplasm.